First in a family of unique devices to assist physicians in diagnosing and managing cardiac arrhythmiasUtilizing cellular technology in diagnostic arrhythmia monitoring provides advantages to both the patient and the clinician. Arrhythmia monitors are typically worn by a patient for a 30-day period, with events manually recorded and then transmitted acoustically over land lines by the patient.

With the new wireless monitor, the recorded event and symptoms will be transmitted automatically through the cellular network, with acoustic transmission still available if necessary.
This increases the ease of use of the device for the patient, and therefore increases a patient’s compliance with the prescribed testing, resulting in a higher diagnostic yield of information for the clinician.

The new cellular device will be offered by SHL’s US telemedicine operation as part of its Diagnostic Arrhythmia Service, and is the platform technology for a proprietary wireless ambulatory continuous monitoring service that is projected to be available early in the coming
months. The integration of cellular technology into the devices that support the arrhythmia services, and the near-term introduction of a state-of-the-art ambulatory continuous monitoring service, will give SHL the most extensive range of cellular-based service options available in the US market.

“We are pleased to begin the introduction of this new family of devices to the US market, says Erez Alroy, Co-CEO of SHL-Telemedicine. We have built our technology to solve the problems
inherent in today’s arrhythmia monitoring devices that make it difficult for physicians to manage their patients’ conditions. With the new cellular looper and the ambulatory continuous monitoring solution to follow in the near term, we anticipate helping our clinicians address key clinical needs and improve patient management and outcomes.”

Download Press Release